Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Dec 14, 2022

Robert Hoffman President, CEO, and Chairman of the Board at Kintara Therapeutics, is developing a drug to treat glioblastoma, the most common and deadliest form of brain tumor. The only drug temozolomide, TMZ, was approved in 1999 and the overall survival rate is very limited. The Kintara drug VAL-083 crosses the blood-brain barrier and is also showing promise for pediatric brain tumors and some ovarian cancers.

Robert explains, "The mechanism of VAL-083 differs from other key chemotherapeutic agents, including TMZ. It induces interstrand cross-links at guanine N07, causing DNA double-strand break and cancer cell death. If you compare that to TMZ, it only induces a single-strand DNA break at N07, and the tumor cells can repair them. That's really an important distinction of our mechanism of action. So, we're really, really excited."

"So, I could imagine once it's approved, physicians would potentially combine it with TMZ, potentially which still may happen. Or Avastin, potentially. So, yes, there is a possibility for that. We're looking at, coincidentally, ovarian cancer with VAL-083 with some PARP inhibitors. So, there are other potential combinations that we're looking at down the road, as well."

"Another underserved area is pediatric brain tumors. We're looking at DIPG, which is a pediatric indication, as well as medulloblastoma"

@Kintara_Thera #Kintara #GBM #Glioblastoma #Cancer #BrainCancer #BrainTumor

Download the transcript here